Gavis: Dedicated to Bringing Niche Products to Market First

Generic SupplementsGeneric Supplement 2015

Founded in 2008 by Dr. Veerappan Subramanian, Gavis Pharmaceuticals develops, markets and, in conjunction with its affiliate Novel Laboratories of Somerset, New Jersey, manufactures niche, specialty and dificult-to-make products across a range of therapeutic classes and dosage forms.

Gavis delivers value to its retail pharmacy partners by identifying the needs of patients, prescribers and pharmacies and offering products that provide therapeutic, economic or continuity benefi ts to everyone involved. Often, these are products for which no generic version is available.

More Choices for Patients, Physicians and Pharmacists

The company’s development portfolio focuses on products for gastrointestinal, women’s health and controlled drug substances across a range of dosage forms, including modifi ed-release tablets and capsules, chewable tablets, orally-disintegrating tablets, topical solutions and many more.

Gavis launched its first three products in May 2009 and distributes its products from a state-of-the-art manufacturing and distribution campus with more than 200,000 square feet of facilities in Somerset, New Jersey. Since its debut, Gavis has built — and will continue to expand — a robust pipeline of specialty pharmaceuticals with limited competition.

Recent Product Launches

Gavis has recently introduced 5 new products to the market, providing a broad range of important choices to pharmacists, prescribers and patients.

(1) Oxycodone Hydrochloride Oral Solution USP, CII, 100mg/5mL

Gavis' Oxycodone Hydrochloride Oral Solution USP, CII, 100 mg/5 mL is AB-rated to Oxycodone Hydrochloride Oral Solution USP, CII, 100 mg/5 mL, of Lehigh Valley Technologies, Inc.

(2) GaviLyte™-H

GaviLyte-H is the newest addition to the GaviLyte line of bowel-prep products. This 2-liter volume PEG-3350 with bisacodyl delayed-release tablet provides an alternative pre-colonoscopy prep and is now available as a value-branded generic.

Comparable to HalfLytely®*, GaviLyte-H provides a generic 2-liter volume PEG-3350 option to the market. GaviLyte-H comes as a complete kit, including a 2-liter container, fl avor packs, GaviLyte-H powder and one Bisacodyl DR tablet. For more information, visit

(3) Metoclopramide HCL ODT

AB-rated to Metzolv®*, Metoclopramide hydrochloride orally disintegrating tablets are available in 5 mg strength in a 10x10 unit dose package.

(4) Doxycycline Capsules USP

AB-rated to Monodox®* Doxycycline Monohydrate capsules, GAVIS’s Doxycycline Capsules USP are available in 50 mg, 75 mg and 100 mg strengths.

(5) Methylphenidate HCl Chewable Tablets, CII

Gavis Pharmaceuticals recently announced the launch of Methylphenidate HCI Chewable tablets, CII, as a generic. This chewable tablet offers an alternative for children who have difficulty swallowing tablets.1, 2

AB-rated to Methylin®* Chewable tablets, Methylphenidate HCl Chewable tablets offer convenient, precise dosing — all in a grape flavored chewable tablet. Methylphenidate HCl Chewable tablets are available in 2.5 mg, 5 mg and 10 mg doses.

Gavis Pharmaceuticals continues to focus on listening to the needs of patients, physicians and pharmacists and delivering solutions that meet those needs through a range of value- branded and generic products. Learn more at


  • “Oral administration of medicines to children — are there any problems?” Steffensen GK, Pachai A, Pederson SE
  • “Pill swallowing ability and training in children 6 to 11 years of age.” Meltzer EO, Welch MJ, Ostrom NK, Clinical Pediatrics (Phila) Oct 2006

Related Videos
Practice Pearl #1 Active Surveillance vs Treatment in Patients with NETs
© 2024 MJH Life Sciences

All rights reserved.